South Korea · Delayed Price · Currency is KRW Daehan Nupharm Statistics
Total Valuation
Daehan Nupharm has a market cap or net worth of KRW 96.98 billion. The enterprise value is 154.41 billion.
| Market Cap | 96.98B |
| Enterprise Value | 154.41B |
Important Dates
The last earnings date was Monday, September 1, 2025.
| Earnings Date | Sep 1, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Daehan Nupharm has 14.04 million shares outstanding.
| Current Share Class | 14.04M |
| Shares Outstanding | 14.04M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 39.26% |
| Owned by Institutions (%) | 0.38% |
| Float | 8.24M |
Valuation Ratios
The trailing PE ratio is 9.47.
| PE Ratio | 9.47 |
| Forward PE | n/a |
| PS Ratio | 0.48 |
| PB Ratio | 0.77 |
| P/TBV Ratio | 0.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 15.00 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.14, with an EV/FCF ratio of -3.81.
| EV / Earnings | 15.08 |
| EV / Sales | 0.77 |
| EV / EBITDA | 8.14 |
| EV / EBIT | 10.43 |
| EV / FCF | -3.81 |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.64.
| Current Ratio | 1.60 |
| Quick Ratio | 0.97 |
| Debt / Equity | 0.64 |
| Debt / EBITDA | 4.21 |
| Debt / FCF | -2.00 |
| Interest Coverage | 8.53 |
Financial Efficiency
Return on equity (ROE) is 8.24% and return on invested capital (ROIC) is 5.07%.
| Return on Equity (ROE) | 8.24% |
| Return on Assets (ROA) | 4.38% |
| Return on Invested Capital (ROIC) | 5.07% |
| Return on Capital Employed (ROCE) | 8.88% |
| Revenue Per Employee | 883.85M |
| Profits Per Employee | 44.90M |
| Employee Count | 228 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 2.94 |
Taxes
In the past 12 months, Daehan Nupharm has paid 2.53 billion in taxes.
| Income Tax | 2.53B |
| Effective Tax Rate | 19.79% |
Stock Price Statistics
The stock price has decreased by -17.20% in the last 52 weeks. The beta is 0.47, so Daehan Nupharm's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -17.20% |
| 50-Day Moving Average | 7,271.00 |
| 200-Day Moving Average | 7,145.00 |
| Relative Strength Index (RSI) | 34.34 |
| Average Volume (20 Days) | 18,716 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Daehan Nupharm had revenue of KRW 201.52 billion and earned 10.24 billion in profits. Earnings per share was 729.37.
| Revenue | 201.52B |
| Gross Profit | 94.86B |
| Operating Income | 15.16B |
| Pretax Income | 12.76B |
| Net Income | 10.24B |
| EBITDA | 19.33B |
| EBIT | 15.16B |
| Earnings Per Share (EPS) | 729.37 |
Balance Sheet
The company has 23.90 billion in cash and 81.32 billion in debt, giving a net cash position of -57.42 billion or -4,091.29 per share.
| Cash & Cash Equivalents | 23.90B |
| Total Debt | 81.32B |
| Net Cash | -57.42B |
| Net Cash Per Share | -4,091.29 |
| Equity (Book Value) | 126.74B |
| Book Value Per Share | 9,030.34 |
| Working Capital | 39.25B |
Cash Flow
In the last 12 months, operating cash flow was 6.46 billion and capital expenditures -47.04 billion, giving a free cash flow of -40.58 billion.
| Operating Cash Flow | 6.46B |
| Capital Expenditures | -47.04B |
| Free Cash Flow | -40.58B |
| FCF Per Share | -2,891.09 |
Margins
Gross margin is 47.07%, with operating and profit margins of 7.52% and 5.08%.
| Gross Margin | 47.07% |
| Operating Margin | 7.52% |
| Pretax Margin | 6.33% |
| Profit Margin | 5.08% |
| EBITDA Margin | 9.59% |
| EBIT Margin | 7.52% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 100.00, which amounts to a dividend yield of 1.44%.
| Dividend Per Share | 100.00 |
| Dividend Yield | 1.44% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 13.71% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.44% |
| Earnings Yield | 10.56% |
| FCF Yield | -41.84% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Daehan Nupharm has an Altman Z-Score of 2.21 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.21 |
| Piotroski F-Score | 5 |